Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor α

This publication has 30 references indexed in Scilit:

• Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα
  Annals of the Rheumatic Diseases, 2001
• Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study
  Annals of the Rheumatic Diseases, 2000
• Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease
  New England Journal of Medicine, 1999
• ANTI-TUMOR NECROSIS FACTOR-α MONOCLONAL ANTIBODY THERAPY FOR RHEUMATOID ARTHRITIS
  Rheumatic Disease Clinics of North America, 1998
• Long-term evolution of gut inflammation in patients with spondyloarthropathy
  Gastroenterology, 1996
• Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
  Arthritis & Rheumatism, 1995
• Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
  Molecular Immunology, 1993
• The European Spondylarthropathy Study Group Preliminary Criteria for the Classification of Spondylarthropathy
  Arthritis & Rheumatism, 1991
• Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study.
  Gut, 1981
• Controlled trial of sulphasalazine in the treatment of ulcerative colitis
  Gut, 1964